Lyra’s LYR-210 Drug Matrix Shows Anti-Inflammatory Effects in Chronic Rhinosinusitis Patients

Lyra Therapeutics is a clinical-stage pharmaceutical company focused primarily on developing and testing new treatments for ear, nose and throat diseases. On September 10, they announced exciting data for their drug LYR-210, a novel treatment directed toward treating chronic rhinosinusitis. This announcement was made at the 66th Annual Meeting of the American Rhinologic Society, in Boston Massachusetts.